Full-Time
Sales Specialist
Labor
Henry Schein
10,001+ employees
Global healthcare product distributor and services
No salary listed
Hamburg, Germany
In Person
Travel is required throughout Northern Germany, including Schleswig-Holstein, Hamburg, Mecklenburg-Western Pomerania, Bremen, and northern Lower Saxony.
 Sales & Account Management (1) |
|---|
Get referred to Henry Schein
See people who can refer or advise you
- Demonstrated experience in the dental laboratory field.
- Commercial expertise.
- Strong customer and service orientation.
- Good Microsoft Office skills.
- Strong communication and organizational skills.
- Structured, independent, and goal-oriented working style.
- High enthusiasm, assertiveness, and negotiation skills.
- Willingness to travel throughout the Northern Germany sales territory, including Schleswig-Holstein, Hamburg, Mecklenburg-Western Pomerania, Bremen, and northern Lower Saxony.
- Technical understanding, particularly of dental laboratory equipment technology.
- Knowledge of dental consumables is desirable.
- Actively sell the existing product range.
- Acquire new customers and continuously expand the existing customer base.
- Work closely with and support sales representatives in the respective region through training, coaching, and lead ownership.
- Actively support and advise on planned product-range expansions.
- Conduct sales and training events for dentists and laboratories.
- Organize regional and nationwide user meetings.
- Develop regional and nationwide key opinion leaders.
- Knowledge of dental consumables.
Henry Schein is a global supplier of healthcare products and services. It operates in two segments: healthcare distribution, which provides dental and medical consumables, equipment, and laboratory products to dentists, physicians, and veterinarians; and technology and value-added services, which offers practice management software, e-commerce solutions, and financial services. The company works by supplying healthcare professionals with a broad range of products and by offering software, online tools, and financing options to run their practices more efficiently. Compared with competitors, Henry Schein combines a wide product catalog with software and financial services, creating a one-stop platform for practice needs across more than 30 countries, with a strong focus on North America. Its goal is to be a trusted partner for healthcare professionals by supporting their day-to-day operations and growth through integrated distribution, technology, and financing solutions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Town of Huntington, New York
Founded
1932
Get referred to Henry Schein
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $3.46 billion, and management raised full-year guidance on August 4.
- US dental merchandise sales rose 8.3% in Q2 2026, showing share gains.
- Value-creation savings start in Q3 2026, with Q4 earnings expected above Q3.
What critics are saying
- Henry Schein faces ongoing antitrust litigation baggage from the Benco and Patterson dental conspiracy cases.
- The July 30, 2026 leadership overhaul removes Ettinger, Mlotek, and Mullins, signaling instability.
- Freight, tariff, and restructuring costs threaten margins if Q3 2026 savings slip.
What makes Henry Schein unique
- Henry Schein serves over one million dental, medical, and veterinary customers globally.
- Its 2026 value-creation plan targets $200 million operating income improvement and one-platform execution.
- The company combines distribution, practice software, e-commerce, and financing in one vendor stack.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Parental Leave
Short Term Disability
Health Savings Account/Flexible Spending Account
Education Benefits
Growth & Insights and Company News
6 month growth
↑ 6%1 year growth
↑ 6%2 year growth
↑ 6%Henry Schein reported second-quarter results that exceeded Wall Street expectations, with revenue of $3.46 billion versus analyst estimates of $3.37 billion and adjusted EPS of $1.27 versus $1.24 expected. The company attributed the performance to accelerating internal sales growth and robust gains in its global dental merchandise segment. CEO Frederick Lowery highlighted success in converting occasional buyers into regular customers and strong market share gains in the US and Canada. The company slightly raised its full-year adjusted EPS guidance to $5.34 at the midpoint. During the earnings call, analysts questioned the sustainability of US dental consumables growth and the timing of value creation benefits. CFO Ronald South indicated most operating income improvements from these initiatives would materialise in the second half of the year.
Henry Schein reported second-quarter sales of $3.5 billion, up 6.7% year-over-year, driven by 4.6% internal local-currency growth and foreign exchange benefits. The healthcare distributor raised its full-year guidance following stronger-than-expected performance. GAAP net income rose to $94 million, or $0.82 per diluted share, from $86 million a year earlier. Non-GAAP earnings reached $1.27 per share, up 15.5% from $1.10 in the prior-year period. Operating margins expanded across all segments. GAAP operating margin increased 27 basis points to 4.94%, whilst non-GAAP operating margin grew 25 basis points to 7.21%. US dental merchandise sales climbed 8.3%, including 6.5% internal growth, with the company reporting market-share gains. Chief Executive Officer Fred Lowery attributed results to operational execution and early benefits from its value-creation programme.
Henry Schein (HSIC), a $9 billion healthcare distribution company, has underperformed the Nasdaq Composite despite recent gains. The stock is up 5.7% over three months, trailing the Nasdaq's 19.2% rise during the same period. Year-to-date, HSIC has gained 4.1% compared to the Nasdaq's 12.6% advance. The Melville, New York-based company, which supplies dental, medical and laboratory products to over one million customers, reported stronger-than-expected first-quarter results on 5 May. Adjusted earnings per share of $1.32 beat analyst estimates of $1.20, whilst revenue of $3.4 billion exceeded forecasts of $3.3 billion. Despite softer medical segment demand from a milder flu season, strength in Home Solutions and technology offerings offset the impact. The company expects full-year adjusted EPS between $5.23 and $5.37.
Eleven Black CEOs currently lead Fortune 500 companies, representing just 2% of America's largest corporations but marking a record high that has doubled since 2021. These companies collectively generated $432 billion in revenue and hold a combined market value of $405 billion. The roster includes Marvin Ellison of Lowe's, the first Black CEO to lead two different Fortune 500 companies, and Thasunda Brown Duckett of TIAA, one of only two Black women currently serving as Fortune 500 chief executives. Other leaders include Peter Akwaboah (Fannie Mae), Christopher Womack (Southern Company), and Calvin Butler (Exelon). Despite comprising 14% of the overall US workforce, Black employees represent only 7% of managers and 4-5% at senior levels, according to McKinsey research. Throughout Fortune 500 history, only 28 Black CEOs have led these companies.
Henry Schein reported first-quarter revenue of $3.37 billion, beating analyst estimates of $3.34 billion, with adjusted earnings per share of $1.32 surpassing expectations of $1.22. The healthcare distributor's performance was driven by strong gains in US dental and global technology segments. CEO Frederick Lowery attributed growth to market share gains and stable dental procedure volumes, supported by merchandise price increases and investments from dental service organisations. The medical business faced headwinds from a lighter flu season affecting point-of-care diagnostics. Analysts questioned gross margin sustainability amid rising oil prices and earnings growth prospects without restructuring. Management highlighted dynamic pricing and proprietary brand growth as margin protection strategies. The company reiterated full-year adjusted EPS guidance of $5.30 at the midpoint, with market capitalisation reaching $7.86 billion.